Close

VOLUNTARY ANNOUNCEMENT - AK112-309/HARMONI-GI1 MET PRIMARY ENDPOINT OF OS IVONESCIMAB PLUS CHEMO DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL OS BENEFIT VERSUS DURVALUMAB PLUS CHEMO IN 1L BTC

Attachments

HKEX-EPS_20260826_12299372_0.PDF